Alexandria — 2021 Investments
8 investments dated 2021 · listed companies and verified rows first · show all
Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need.
BiotechHealthtech
John Quisel(Chief Executive Officer)inJean Franchi(Chief Financial Officer)inJonathan Yu(Chief Operating Officer)inWill Savage(Chief Medical Officer)inPamela Stephenson(Chief Commercial Officer)inSteve Caffé(Chief Regulatory Officer)in
Co-investorsAccess BiotechnologyAtlas VentureBain Capital Life SciencesForesite CapitalFrazier Life SciencesOrbiMed+6 more
Asher Bio develops selective immunotherapy drugs that target specific immune cell types to promote beneficial effects while minimizing toxicity.
BiotechHealthtechMedical DevicesSan Francisco, US
Ivana Djuretic(Founder)inAndy Yeung(Founder)in
Co-investorsEmles Venture PartnersGoAhead VenturesMission Bay CapitalMission BiocapitalRA CapitalY Combinator+4 more
Bright Peak Therapeutics is a biotechnology company developing multi-functional PD-1 inhibitors for cancer immunotherapy, based on its EDC protein-engineering platform.
BiotechHealthtechSan Diego, US
Vijaya Pattabiraman(Co-founder & Chief Technology Officer)inJeffrey Bode(Scientific Co-founder)inFredrik Wiklund(Chief Executive Officer)Christine Siu(Director)Michael Rosenzweig(Director)Bertolt Kreft(Executive Officer)
Co-investorsRA CapitalJohnson & Johnson Innovation – JJDCVersant VenturesVenrockBlackRockFidelity Investments+2 more
Fountain is a biotech company developing first-in-class therapies for diseases and conditions caused by aging, using in vitro and in vivo screening platforms to identify drug candidates.
BiotechHealthtechLongevitySan Francisco, US
Thomas Rando(Co-founder)Joseph Rodgers(Co-founder)inTom Cheung(Co-founder)inTsang(Chief Business Officer)
Co-investorsKhosla VenturesNan Fung Life SciencesR42 Group
Immunai develops AMICA, a data platform for decoding the immune system to accelerate drug discovery and development.
AI & Machine LearningBiotechData & InfrastructureNew York City, US
Co-investorsCatalio Capital Management, LPGefen CapitalKoch Disruptive TechnologiesMeron CapitalPerot JainTLV Partners+2 more
IpiNovyx Bio is a biotech company developing potent and selective immunoproteasome inhibitors to treat cancer, autoimmune, and inflammatory diseases.
BiotechHealthtechMedical DevicesWest Nyack, US
Gang Lin(Scientific Founder)Carl Nathan(Scientific Founder)Franck Barrat(Scientific Founder)inMarc Appel(Executive Officer, Director)Lutz Giebel(Director)James Graham(Director)
Co-investorsPathway Bioventures
Kytopen develops non-viral gene delivery technology called Flowfect that combines fluid flow with electric fields to deliver payloads such as mRNA, DNA, and CRISPR Cas9 RNP into cells for high-throughput transfection.
BiotechDeep TechHardwareCambridge, US
Cullen Buie(Director)inPaulo Garcia(Executive Officer, Director, Promoter)inMichael Chiu(Director, Executive Officer)in
BoardPaxton Major(Director)Ann DeWitt(Director)inPaul Wotton(Director)
Co-investorsBantam GroupHorizons VenturesMassVenturesSelvedge VentureTBD AngelsTelegraph Hill Partners+2 more
AgTechHarrisonburg, US
Barbara Kite(Vice President of Finance and Human Resources)Steve Wright(Vice President of Sales and Purchasing)Robert Hoffman(Chief Technology Officer)Philip Karp(Chief Operating Officer)Ilir Cela(Executive Officer)Timothy Heydon(President and Chief Executive Officer)
Co-investorsAdvantage Capital PartnersArborview CapitalDns CapitalMiddleland CapitalS2G InvestmentsXPV Water Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.